The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 ...

A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

CRISPR Therapeutics (CRSP) announced positive Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo ...

Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

BANDUNG, itb.ac.id - The PINTAR Diagnostics team from the School of Life Sciences and Technology (SLST), Institut Teknologi ...